PMID- 38410975
OWN - NLM
STAT- MEDLINE
DCOM- 20240404
LR  - 20240404
IS  - 1473-5741 (Electronic)
IS  - 0959-4973 (Linking)
VI  - 35
IP  - 5
DP  - 2024 Jun 1
TI  - The efficacy and safety of adding anlotinib in gradual progression on 
      third-generation EGFR-TKIs for EGFR-mutant advanced nonsmall cell lung cancer.
PG  - 433-439
LID - 10.1097/CAD.0000000000001575 [doi]
AB  - Acquired resistance is unavoidable with the approval of third-generation 
      epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for 
      first-line therapy of advanced non small cell lung cancer (NSCLC). Some studies 
      have found that combining antiangiogenesis medicines with EGFR-TKI may benefit 
      clinical outcomes in EGFR-mutant NSCLC. However, it is unclear whether EGFR-TKI 
      paired with antiangiogenesis therapy could further improve survival for patients 
      with gradual progression. Thus, we comprised the clinical effectiveness and 
      safety of continuous EGFR-TKI in combination with anlotinib and EGFR-TKI alone in 
      patients who had gradual progression on third-generation EGFR-TKI treatment. The 
      comparison of progression-free survival (PFS) and overall survival(OS) between 
      two groups used the Kaplan-Meier method. Our study comprised 121 eligible 
      patients in total. The objective response rates were 25.0% and 0%, and the 
      disease response rate was 91.7% and 86.9% in the combination group and EGFR-TKIs 
      monotherapy group. The median PFS of combined anlotinib and EGFR-TKI treatment 
      was 6.7 months and the median PFS was 3.6 months in the EGFR-TKI monotherapy 
      group ( P  < 0.001). There were no significant differences between the two groups 
      in OS. The common adverse reactions were diarrhea (21.7%), hypertension (21.6%) 
      and proteinuria (20.0%) in the combination group. Seven patients experienced a 
      grade 3 or higher adverse event, no patients discounted the treatment or died due 
      to the toxicity. Our study indicated that, when combined with anlotinib following 
      gradual progression on EGFR-TKIs, it was more efficacious for EGFR-mutant NSCLC 
      patients than EGFR-TKI monotherapy. And the toxicity was clinically manageable.
CI  - Copyright (c) 2024 The Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Xiang, Hai
AU  - Xiang H
AD  - College of Environment and Resources, Zhejiang A&F University.
FAU - Danna, Ding
AU  - Danna D
AD  - College of Environment and Resources, Zhejiang A&F University.
FAU - Xuefei, Chen
AU  - Xuefei C
AD  - College of Environment and Resources, Zhejiang A&F University.
FAU - Zhao, Jinkai
AU  - Zhao J
AD  - The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 
      Zhejiang, China.
FAU - Jin, Guangjun
AU  - Jin G
AD  - The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 
      Zhejiang, China.
LA  - eng
PT  - Journal Article
DEP - 20240222
PL  - England
TA  - Anticancer Drugs
JT  - Anti-cancer drugs
JID - 9100823
RN  - 0 (anlotinib)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - 0 (Indoles)
RN  - 0 (Quinolines)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics
MH  - *Lung Neoplasms/drug therapy/genetics
MH  - Protein Kinase Inhibitors/adverse effects
MH  - ErbB Receptors
MH  - Mutation
MH  - *Indoles
MH  - *Quinolines
EDAT- 2024/02/27 06:45
MHDA- 2024/04/04 06:45
CRDT- 2024/02/27 05:29
PHST- 2024/04/04 06:45 [medline]
PHST- 2024/02/27 06:45 [pubmed]
PHST- 2024/02/27 05:29 [entrez]
AID - 00001813-202406000-00006 [pii]
AID - 10.1097/CAD.0000000000001575 [doi]
PST - ppublish
SO  - Anticancer Drugs. 2024 Jun 1;35(5):433-439. doi: 10.1097/CAD.0000000000001575. 
      Epub 2024 Feb 22.